Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis

Int J Immunopharmacol. 1995 Jul;17(7):597-603. doi: 10.1016/0192-0561(95)00057-9.

Abstract

The effects of Ta-383 (0.016, 0.08, 0.4, 2 and 10 mg/kg) and anti-rheumatic drugs (lobenzarit 10 and 50 mg/kg, dexamethasone 0.25 mg/kg) were evaluated on type II collagen-induced arthritis in DBA/1J mice. The arthritis score was markedly suppressed in the groups treated with dexamethasone and TA-383. Serum anti-type II collagen IgG was significantly suppressed in the groups treated with dexamethasone and 0.4 mg/kg TA-383. Histopathological evaluation of the knee joints revealed suppression of the inflammatory changes in the groups treated with dexamethasone and TA-383. These findings suggest that the histopathological examination of the joints of the animal model is useful for the evaluation of anti-rheumatic drugs, and that TA-383 has suppressive effects on type II collagen-induced arthritis, an animal model for human rheumatoid arthritis.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Arthritis, Experimental / drug therapy*
  • Arthritis, Experimental / immunology
  • Collagen* / immunology
  • Dexamethasone / therapeutic use
  • Humans
  • Imidazoles / therapeutic use*
  • Immunoglobulin G / immunology
  • Male
  • Mice
  • Mice, Inbred DBA
  • ortho-Aminobenzoates / therapeutic use

Substances

  • Anti-Inflammatory Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Imidazoles
  • Immunoglobulin G
  • ortho-Aminobenzoates
  • 2-(4-chlorophenyl)-4,5-diphenyl-2-imidazoline hydrochloride
  • Dexamethasone
  • Collagen
  • lobenzarit